Bezlotoxumab can reduce the risk of Clostridium Difficile recurrence

Authors

  • Asier Mitxelena Osakidetza
  • Maria Areses Osakidetza

Keywords:

Bezlotoxumab, diarrhea, Clostridium Difficile, toxin, antitoxin

Abstract

Compared to placebo, Bezlotoxumab reduces 10% the risk of recurrence of Clostridium Difficile (17% vs 27%; 95% CI: -15 to -4) in MODIFY I trial, and very similar results are obtained in MODIFY II trial (-10%; 16% vs 26%; 95% CI: -15 to -4). The addition of actoxumab to bezlotoxumab did not improve efficacy (-11%; 16% vs 28%; 95% CI: -17 to -6).

Author Biographies

Asier Mitxelena, Osakidetza

Barne-Medikuntzako medikua Santa Marina Ospitalean

Maria Areses, Osakidetza

Barne-Medikuntzako medikua Santa Marina Ospitalean

Downloads

Published

2022-07-29

How to Cite

Mitxelena, A., & Areses, M. (2022). Bezlotoxumab can reduce the risk of Clostridium Difficile recurrence. Osagaiz: Osasun-Zientzien Aldizkaria, 6(1). Retrieved from https://aldizkariak.ueu.eus/index.php/osagaiz/article/view/362

Issue

Vol. 6 No. 1 (2022)

Section

Kritikoki Aztertutako Testuak